We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
India, Hyderabad, 3rd January 2018: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, today announces the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘MaburaTM’ in India. The product will be marketed and distributed by Hetero Healthcare in the country.
MaburaTM is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis etc. MaburaTM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously.
Hetero’s MaburaTM is the Biosimilar version of AbbVie’s HumiraTM. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.
The product will be manufactured at our dedicated state-of-the-art manufacturing facility for Biologics, based at Hyderabad, India.
About Hetero
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 20 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars and custom pharmaceutical services. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.
Hetero has 33 state-of-the-art manufacturing facilities strategically located worldwide. And a majority of our facilities have been successfully audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.
Hetero has a strong global presence in over 120 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com.
Media Contact:
Jeyasingh Balakrishnan Head – Corporate Communications Hetero Labs Limited, India Mobile: +91 9989626541/ +91 9833836185 Email: Jeyasingh.b@heterodrugs.com